Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA-Guided Early Second Infusion of Axi-Cel in R/R DLBCL
NCT06902012Phase 2Recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Feb 2027
- Primary completion
- Feb 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), Transformed Follicular Lymphoma (tFL), high grade B-cell lymphoma (HGBCL), sponsored by Southern Medical University Zhujiang Hospital. Planned start Feb 2027; status: recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)Transformed Follicular Lymphoma (tFL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT06902012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06902012.